Schering Aktiengesellschaft

Inhale Therapeutic Systems, Inc.

Actipac Biosystems Gmbh

Berlirem Gmbh

Sinoxa Pharma Gmbh

Neurobiotec Gmbh

Johannes Wilhelm Tack

Celal Albayrak

Ralph Lipp

Reinhard Horowski

Jutta Riedl

Reinhard Schmitz

Georg R&ouml;ssling

Karin Schmidt-Gollwitzer

Georg Rossling

Ralf Wyrwa

Thomas Backensfeld

Wolfgang Heil

Helmut Kaeufer

Rudolf Reiter

Wolfgang Stindl

Renate Heithecker

Michael Humpel

Fred Windt-Hanke

Ulrich Taeuber

Hans-Martin Wache

Matthias Schnalbelrauch

Thomas Mueller

Peter Ewert

Juergen Weisser

Michael Huempel

Juergen Hilman

Christoph Voelkel

Christian Fechner

Erich Leitner

Thorsten Laube

Erwin Dargel

Gesine Hildebrand

Clemens Guenther

The present invention relates to novel compounds of the formula I, methods for their preparation and their use for treatment of diseases. The invention discloses the synthesis of levodopa (L-DOPA) esters by coupling polyhydroxy compounds or their derivatives to the L-DOPA carboxyl group. The synthesis allows to produce L-DOPA derivatives which are highly soluble in water as well as aqueous and biocompatible liquids and have an improved hydrolytic stability in water or aqueous and biocompatible media for an application over several days. The invention helps producing L-DOPA substances for applications in the fields of medicine, biology and medical engineering as well as in the pharmaceutical industry.

Water-soluble L-DOPA esters

The present invention relates to the use of ergot derivatives or ergolines, and in particular of lisuride and terguride for the prophylaxis and treatment of constrictive capillary arteriopathy. Constrictive capillary arteriopathy refers to the diseases pulmonary arterial hypertension, endogenously induced or exogenously induced glomerulosclerosis as well as secondary Raynaud's syndrome.

Pharmaceutical compositions for the treatment of capillary arteriopathy

The invention relates to the use of a dopamine agonist in the form of an agent consisting of at least two spatially discrete compositions, of which one is a transdermal therapeutic system (TTS) containing the dopaminergic agent and another one or more are preparations for oral and/or parenteral application containing that same dopaminergic agent for the treatment of dopaminergically treatable diseases with the following elements: a) the TTS is continuously applied, b) within the duration of application in a) the composition for oral or parenteral dosage is administered.

Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states

New tubular vascular implants (stents) that consist of biocompatible, thermoplastic material that have a shape memory and that contain at least one active ingredient are described. In addition, a process for their production and their use as vascular implants for prophylaxis of restenosis are described.

Tubular vascular implants (stents) and methods for producing the same

Pharmaceutical composition for use as a contraceptive

The invention relates to a process for the production of morphologically uniform microcapsules that contain peptides, proteins or other water-soluble biologically active substances as active ingredients as well as microcapsules that are produced according to this process with a degree of concentration of between 3 to 30% by weight and a diameter &lE;8 &mgr;m. According to the invention, biodegradable polymers are dissolved in a halogen-free solvent or solvent mixture, and the buffered active ingredient solution, which has a pH of between 6.0 to 8.0, is dispersed into this solution. Then, an aqueous solution that contains a surfactant (W/O/W-emulsion) is added to this W/O-emulsion, and the solvent is removed. The microcapsules that are produced with this process do not show any tendency toward agglomeration. The encapsulation efficiency of the process is approximately 90 to 95%.

Process for the production of morphologically uniform microcapsules and microcapsules that are produced according to this process

Method of producing morphologically uniform microcapsules and microcapsules produced by this method

Solid dosage forms that contain clathrates of 17.alpha.-ethinyl estradiol

An agent for transdermal administration contains gestodene, optionally in combination with one or more estrogen(s).

Gestodene-containing agent for transdermal administration

A method of using cavitate- or clathrate-forming host/guest complexes for the preparation of contrast media in ultrasonic examination is provided. The host/guest complexes have a host which dissolves in a liquid carrier, releasing the guest (inert gas). With such contrast media, it is possible to diagnose blood and its flow conditions in the heart, and other organs, such as the myocardium, liver, spleen, and kidneys. Other internal systems such as the urinary ducts, the gastrointestinal tract, joints, and eyes can also be imaged.

Preparation comprising cavitate-  or clathrate-forming host/guest

A transdermal therapeutic system is described, which is characterized in that it contains a crystallization inhibitor and optionally penetration enhancer in an active ingredient-containing adhesive matrix.

Transdermal therapeutic systems with crystallization inhibitors

Process for the production of semisolid preparations containing

Medicinal agents are claimed exhibiting sustained release of active compound, containing a solid active ingredient, poorly soluble in water, and auxiliary agents, characterized in that the active compound, in a microcrystalline form or in form of a molecular dispersion, is distributed in or on pellets, and that the pellets are covered by a membrane having retarded permeability with respect to the active compound.

Medicinal agents with sustained action

Growing community of inventors

Berlin, Germany

Johannes Wilhelm Tack